SCHEMBL23728467

SCHEMBL23728467

C=Cc1cnc2c(C(=O)OCC)cnn2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.53
HPGD P15428 6/20 0.53
KDM4E B2RXH2 7/20 0.52
RAB9A P51151 6/20 0.52
NPC1 O15118 5/20 0.52
HSD17B10 Q99714 4/20 0.43
LMNA P02545 2/20 0.43
CSNK1D P48730 1/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
POLB P06746 2/20 0.41
NFKB1 P19838 2/20 0.41
NFKB2 Q00653 2/20 0.41
RELA Q04206 2/20 0.41
HTT P42858 1/20 0.41
RECQL P46063 1/20 0.41
MAPT P10636 1/20 0.41
KMT2A Q03164 1/20 0.40
PDE4B Q07343 1/20 0.40
TP53 P04637 1/20 0.40
STAT1 P42224 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17781274 0.83 KDM4E (0.57) ALDH1A1HPGDKDM4ERAB9ANPC1
SCHEMBL23728526 0.82 ALDH1A1 (0.56) ALDH1A1HPGDKDM4ERAB9ANPC1
SCHEMBL23728550 0.82 ALDH1A1 (0.56) ALDH1A1HPGDKDM4ERAB9ANPC1
SCHEMBL23728514 0.82 KDM4E (0.39) ALDH1A1HPGDKDM4EHSD17B10LMNA
SCHEMBL309140 0.81 ALDH1A1 (0.55) ALDH1A1HPGDKDM4ERAB9ANPC1
SCHEMBL14033767 0.81 ALDH1A1 (0.55) ALDH1A1HPGDKDM4ERAB9ANPC1
SCHEMBL23728472 0.81 ALDH1A1 (0.55) ALDH1A1HPGDKDM4ERAB9ANPC1
SCHEMBL23728470 0.80 ALDH1A1 (0.54) ALDH1A1HPGDKDM4ERAB9ANPC1
SCHEMBL23728532 0.79 ALDH1A1 (0.55) ALDH1A1HPGDKDM4ERAB9ANPC1
SCHEMBL23728603 0.79 KDM4E (0.55) ALDH1A1HPGDKDM4ERAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-20 US disclosed
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-20 US disclosed
EP-4100004-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2022-12-14 EP disclosed
WO-2021158634-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-08-12 WO disclosed
WO-2021158634-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 ALDH1A1 2776/4885HPGD 3843/4885KDM4E 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.